- Home
- NITO vs PMCB Comparison
NITO vs PMCB Comparison
Compare NITO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- PMCB
- Stock Information
- Founded
- NITO 2009
- PMCB 1996
- Country
- NITO Israel
- PMCB United States
- Employees
- NITO N/A
- PMCB N/A
- Industry
- NITO
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NITO
- PMCB Health Care
- Exchange
- NITO NYSE
- PMCB Nasdaq
- Market Cap
- NITO 6.6M
- PMCB 7.3M
- IPO Year
- NITO N/A
- PMCB N/A
- Fundamental
- Price
- NITO $0.31
- PMCB $0.96
- Analyst Decision
- NITO
- PMCB
- Analyst Count
- NITO 0
- PMCB 0
- Target Price
- NITO N/A
- PMCB N/A
- AVG Volume (30 Days)
- NITO 2.3M
- PMCB 26.5K
- Earning Date
- NITO 08-13-2025
- PMCB 09-16-2025
- Dividend Yield
- NITO N/A
- PMCB N/A
- EPS Growth
- NITO N/A
- PMCB N/A
- EPS
- NITO N/A
- PMCB 1.29
- Revenue
- NITO $232,000.00
- PMCB N/A
- Revenue This Year
- NITO N/A
- PMCB N/A
- Revenue Next Year
- NITO N/A
- PMCB N/A
- P/E Ratio
- NITO N/A
- PMCB $0.74
- Revenue Growth
- NITO 24.74
- PMCB N/A
- 52 Week Low
- NITO $0.16
- PMCB $0.95
- 52 Week High
- NITO $3.49
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- NITO 62.62
- PMCB 33.92
- Support Level
- NITO $0.25
- PMCB $0.95
- Resistance Level
- NITO $0.37
- PMCB $1.04
- Average True Range (ATR)
- NITO 0.02
- PMCB 0.08
- MACD
- NITO 0.01
- PMCB -0.02
- Stochastic Oscillator
- NITO 58.87
- PMCB 2.50
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.